FILING ANALYSIS · TUESDAY, NOVEMBER 10
Ovid Therapeutics Inc. OVID — 8-K: Results of Operations and Financial Condition
neutral
Ovid Therapeutics reported a cash position of $161.4 million, expected to last into 2029, and provided updates on its pipeline, including the advancement of OV329 in a global Phase 2 focal epilepsy study and the progression of OV4071 in a Phase 1 single- and multiple-ascending dose study, but no significant quantified surprises were disclosed
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →